Inventor
PADLAN EDUARDO A
US25 patents
⚠️ This page may combine multiple inventors who share the name “PADLAN EDUARDO A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
13 patentsUS6818749B1Nov 16, 2004
Variants of humanized anti carcinoma monoclonal antibody cc49
US HEALTH133 citations98
US5889157AMar 30, 1999
Humanized B3 antibody fragments, fusion proteins, and uses thereof
US HEALTH64 citations95
US7256004B2Aug 14, 2007
Variants of humanized anti-carcinoma monoclonal antibody CC49
US HEALTH21 citations92
US7589181B2Sep 15, 2009
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US HEALTH6 citations73
US7179899B2Feb 20, 2007
Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
US HEALTH5 citations73
US6287562B1Sep 11, 2001
Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
US HEALTH9 citations73
US8835167B2Sep 16, 2014
Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors
US HEALTH2 citations62
US8029788B2Oct 4, 2011
Variants of humanized anti-carcinoma MAb CC49
US HEALTH2 citations62
US7919607B2Apr 5, 2011
Nucleic acids encoding humanized anti-tag 72 CC49 antbodies
US HEALTH3 citations62
US7915396B2Mar 29, 2011
Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized antibody CC49
US HEALTH3 citations62
US7569673B2Aug 4, 2009
Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
US HEALTH3 citations62
US7763719B2Jul 27, 2010
Variants of humanized anti-carcinoma MAb CC49
US HEALTH0 citations52
US7855276B2Dec 21, 2010
Framework residue substituted humanized COL-1 antibodies and their use
US HEALTH0 citations46
IDEC PHARMA CORP
3 patentsUS6001358ADec 14, 1999
Humanized antibodies to human gp39, compositions containing thereof
IDEC PHARMA CORP125 citations99
US6440418B1Aug 27, 2002
Methods of treating autoimmune diseases with gp39-specific antibodies
IDEC PHARMA CORP36 citations92
US6506383B1Jan 14, 2003
Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies
IDEC PHARMA CORP9 citations74